Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052841 | 1.00 | PTPN1 (0.48) | PTPN1TSHRCTSLCTSKALDH1A1 | |
| SCHEMBL12052840 | 0.93 | PTPN1 (0.48) | PTPN1CTSLCTSKALDH1A1MDM2 | |
| SCHEMBL8100860 | 0.93 | PTPN1 (0.48) | PTPN1CTSLCTSKALDH1A1MDM2 | |
| SCHEMBL12605223 | 0.89 | ALDH1A1 (0.55) | PTPN1ALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL12062867 | 0.88 | TSHR (0.54) | PTPN1TSHRALDH1A1THRBCYP2C9 | |
| SCHEMBL13437618 | 0.88 | TSHR (0.54) | PTPN1TSHRALDH1A1THRBCYP2C9 | |
| SCHEMBL14326321 | 0.88 | KLK5 (0.43) | PTPN1TSHRALDH1A1THRBCYP2C9 | |
| SCHEMBL14326319 | 0.87 | KLK5 (0.42) | PTPN1TSHRALDH1A1THRBCYP2C9 | |
| SCHEMBL14326320 | 0.87 | KLK5 (0.42) | PTPN1TSHRALDH1A1THRBCYP2C9 | |
| SCHEMBL17444826 | 0.85 | PTPN1 (0.48) | PTPN1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8080545-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | PTPN1 1676/4885TSHR 4716/4885CTSL 724/4885 |
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | PTPN1 1676/4885TSHR 4716/4885CTSL 724/4885 |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | PTPN1 1676/4885TSHR 4716/4885CTSL 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.